• AAPL 165
  • TSLA 147.05
  • AMZN 174.63
  • MSFT 399.12
  • INTC 34.2
  • EURUSD 1.0661
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CORT.NASDAQ

Corcept Therapeutics Incorporated (CORT NASDAQ) stock market data APIs

$22.6 -0.35(-1.5%) as of April 19, 2024

Corcept Therapeutics Incorporated Financial Data Overview

22.95
22.6
-
23.03
22.56
20.8693-34.275
2 383 M
24.4149
104 M
482 M
0.28
0.477
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CORT',
Type: 'Common Stock',
Name: 'Corcept Therapeutics Incorporated',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BKJG33',
ISIN: NULL,
CUSIP: NULL,
CIK: '1088856',
EmployerIdNumber: '77-0487658',
FiscalYearEnd: 'December',
IPODate: '2004-04-14',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Corcept Therapeutics Incorporated Fundamental Data is available in our Financial Data APIs

  • Net Revenue 482 M
  • EBITDA 108 M
  • Earnings Per Share 0.94
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Corcept Therapeutics Incorporated Earnings via APIs

  • Latest Release 2024-02-15
  • EPS/Forecast 0.26

Get Corcept Therapeutics Incorporated End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Corcept Therapeutics Incorporated latest news via APIs

Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know

Corcept Therapeutics (CORT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimate...

Corcept (CORT) Completes Enrollment in Phase II ALS Study

Corcept Therapeutics Incorporated CORT announced that it has completed enrollment in the phase II DAZALS study, which is evaluating its selective cortisol modulator, dazucorilant, for treating patient...
Do you have any questions?
support@eodhistoricaldata.com